Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 3
2014 1
2016 4
2017 2
2018 5
2019 4
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean hui y yu (3 results)?
A randomized trial on the effect of transcutaneous electrical nerve stimulator on glycemic control in patients with type 2 diabetes.
Lu JY, Ou HY, Wu CZ, Yang CY, Jiang JY, Lu CH, Jiang YD, Chang TJ, Chang YC, Hsieh ML, Wu WC, Li HY, Du YF, Lin CH, Hung HC, Tien KJ, Yeh NC, Lee SY, Yu HI, Chuang LM. Lu JY, et al. Among authors: yu hi. Sci Rep. 2023 Feb 15;13(1):2662. doi: 10.1038/s41598-023-29791-7. Sci Rep. 2023. PMID: 36792682 Free PMC article. Clinical Trial.
Sesamin, a Naturally Occurring Lignan, Inhibits Ligand-Induced Lipogenesis through Interaction with Liver X Receptor Alpha (LXRα) and Pregnane X Receptor (PXR).
Tai TS, Tien N, Shen HY, Chu FY, Wang CCN, Lu CH, Yu HI, Kung FP, Chuang HH, Lee YR, Chang HY, Lim YP. Tai TS, et al. Among authors: yu hi. Evid Based Complement Alternat Med. 2019 Nov 25;2019:9401648. doi: 10.1155/2019/9401648. eCollection 2019. Evid Based Complement Alternat Med. 2019. PMID: 31976003 Free PMC article.
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189511 Clinical Trial.
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):131-138. doi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189509 Clinical Trial.
Proteomic analysis of honokiol-induced cytotoxicity in thyroid cancer cells.
Chou HC, Lu CH, Su YC, Lin LH, Yu HI, Chuang HH, Tsai YT, Liao EC, Wei YS, Yang YT, Chien YA, Yu XR, Lee YR, Chan HL. Chou HC, et al. Among authors: yu hi. Life Sci. 2018 Aug 15;207:184-204. doi: 10.1016/j.lfs.2018.06.002. Epub 2018 Jun 5. Life Sci. 2018. PMID: 29883720
20 results